Showing items related by title and author.

• Cost-effectiveness of etanercept and efalizumab In the management of moderate and severe plaque psoriasis 

  Le Pen, Claude; Feneron, D.; Ortonne, J. P.; Daures, JP.; Ollivier, AL.; Thiriet, Catherine (2008) Article accepté pour publication ou publié
• Indirect costs of rheumatoid arthritis and their Determinants 

  Le Pen, Claude; Schadtler Law, L.; Camara, Catherine; Bardoulat, Isabelle; Maurel, F. (2009-10) Communication / Conférence
• Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation 

  Deconinck, Eric; Miadi-Fargier, Houda; Le Pen, Claude; Brice, Pauline (2010) Article accepté pour publication ou publié
• Impact of rheumatoid arthritis (ra) on working conditions and income 

  Le Pen, Claude; Bardoulat, Isabelle; Preiss, P.; Schadtler Law, L.; Fautrel, B.; Maurel, F. (2009) Article accepté pour publication ou publié
• Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France 

  Chouaid, Christos; Bensimon, Lionel; Clay, Emilie; Millier, Aurélie; Levy-Bachelot, Laurie; Huang, Min; Lévy, Pierre (2019) Article accepté pour publication ou publié